Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.